Shares of Enzo Biochem Inc. (ENZ) are rising over 28% in pre-market today, after the company announced its Comprehensive COVID-19 Program incorporating its molecular diagnostic virus screening products, detection for immunity through IgG/IgM serological ELISA products, detection of inflammation on Enzo's ELISA platform, and a promising proprietary drug candidate (SK1-I).
from RTT - Before the Bell https://ift.tt/3cFyD87
via IFTTT
No comments:
Post a Comment